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Background: Heart disease progression occurs in 30% of patients with chronic Trypanosoma cruzi infection.
Supplementation with selenium (Se) in animal model of T. cruzi infection produced promising results. There is
evidence that patients with Chagas heart disease have lower Se levels than healthy individuals and patients with T.
cruzi infection without of cardiac disease. The aim of this investigation is to estimate the effect of Se treatment on
prevention of heart disease progression in patients with chagasic cardiopathy.
Methods: The Selenium Treatment and Chagasic Cardiopathy trial is a superiority, double-blind, placebo-controlled,
randomized clinical trial. The eligibility criteria are as follows: (1) a Chagas disease diagnosis confirmed by serology;
(2) segmental, mild or moderate global left ventricular systolic dysfunction; and (3) age between 18 and 65 years.
The exclusion criteria are as follows: (1) pregnancy, (2) diabetes mellitus, (3) tobacco use, (4) alcohol abuse,
(5) evidence of nonchagasic heart disease, (6) depression, (7) dysphagia with evidence of food residues in the
esophagus, (8) dysphagia with weight loss higher than 15% of usual weight in the last four months and/or (9)
conditions that may result in low protocol adherence. The intervention will be 100 μg of sodium selenite once daily
for 365 consecutive days compared to placebo. The following are the primary outcomes to be measured: (1) the
trajectories of the left ventricular ejection fraction in the follow-up period; (2) reduction of heart disease progression
rates, with progression defined as a 10% decrease in left ventricular ejection fraction; and (3) rate of hospital
admissions attributable to dysrhythmia, heart failure or stroke due to Chagas disease. One hundred thirty patients
will be randomly allocated into either the intervention or placebo group at a ratio of 1:1. The sequence allocation
concealment and blinding were planned to be conducted with the strategy of numbered boxes. Both patients and
health-care providers will remain blinded to the intervention groups during the 5 years of follow-up.
Discussion: If Se treatment reduces the progression of Chagas cardiopathy, the inclusion of this micronutrient in
the daily diet can improve the therapeutic regimen for this neglected tropical disease at low cost.
Trial registration: Clinical Trials.gov ID: NCT00875173 (registered 20 October 20 2008).
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Chagasic cardiopathy is considered the most common
and serious manifestation of chronic Chagas disease [1].
This specific form of Chagas disease is associated with
high levels of morbidity and mortality [2] and is also a
major component in Chagas disease burden [3].
The probability of death among patients with heart
failure (HF) attributable to Chagas disease is about 80%
over the course of 10 years [4]. According to the Brazilian
consensus on Chagas disease [2], patients with Trypano-
soma cruzi infection and heart disease can be classified
into different stages, depending on the electrocardiog-
raphy (ECG) and echocardiography findings, as follows:
stage A (abnormalities on ECG attributable to Chagas dis-
ease and no abnormalities detected by echocardiography),
stage B1 (abnormal echocardiogram showing ejection frac-
tion (EF) >45% and no HF syndrome), stage B2 (echocar-
diogram showing EF <45% and no HF), stage C (HF with
improvement after treatment optimization) and stage D
(HF with no improvement after treatment optimization)
[2]. This classification is closely related to prognosis, as left
ventricular (LV) function is the strongest predictor of
mortality in Chagas heart disease [4-6].
Selenium (Se) is a vital trace element for all organisms,
and it has been considered the most important antioxi-
dant mineral, being essential to selenoenzymes such as
glutathione-peroxidase (GPx) and others [7]. Se levels vary
among the foods of different countries, and a serum level
lower than 45 μg/L is considered a potential risk factor for
heart disease [8]. The plateau of maximal Se-GPx activity
is reached when the plasma Se concentration ranges from
89 to 114 μg/L [8]. Se function is related to its localization
in active sites in proteins, as well as to how these proteins,
such as GPx, are involved in the protection of biomem-
branes against the attack of free radicals [9].
Some diseases have been correlated with low serum
levels of Se, including AIDS [10], Kashin–Beck disease
[11], myxedematous cretinism [12], prostate cancer [13]
and cardiopathies [8]. In some cases, low Se levels may
be an effect of particular diseases or may contribute to
exacerbation of disease progression.
Nutritional Se deficiency or a low Se level is associated
with some cardiopathies in animals and humans. There is
strong evidence that prolonged Se deficiency in patients
receiving home parenteral nutrition is harmful to the heart
and can contribute to the development of myocardiopathy
[14,15]. Keshan disease is among the cardiopathies that are
classically related to Se deficiency. This condition affects
children and young women of childbearing age in areas of
China and Eastern Siberia with low soil Se levels [16,17].
In addition, it is possible that low Se could contribute to
the development of AIDS-related myocardiopathy [18].
Similar evidence came from autopsic studies of AIDS pa-
tients with heart disease and decreased Se levels [19]. LowSe levels and hyperprolactinemia were reported in patients
with peripartum cardiopathy in Africa’s Sahel region, an
uncommon form of congestive myocardiopathy that oc-
curs in the last month of pregnancy or in the first 6 months
postpartum [20]. Also, Se deficiency may be a contributing
factor in congestive HF that affects malnourished children
with kwashiorkor disease [21]. There is a positive correl-
ation between Se intake and its blood levels [22], and it
has been suggested that Se may play a role in the clinical
severity of HF, as evidence indicates that mean Se intake is
lower in these patients. Ischemic heart disease has also
been linked to low Se levels [23-25].
There is only a single study in which investigators
evaluated the relationship between Se levels and chagasic
cardiopathy in humans [26]. Nevertheless, there is some
consistent evidence showing that low Se levels worsen car-
diopathy in Chagas disease animal models [27,28] and that
Se supplementation is beneficial in Chagas disease cardi-
opathy animal models [29-31]. The mechanisms involved
in this effect are modulation of tissue inflammation and
oxidative stress [32,33].
The occasional ingestion of an elevated dose of Se can
cause signs of toxicity. Such effects may be seen in asso-
ciation with suicide attempts and accidental ingestion
[34]. However, adverse effects seem to be rare and have
been reported only in cases of exposure to Se doses over
400 μg/day [14]. Acute symptoms include irritability, pain
and trembling; tachycardia; nausea, vomiting and abdom-
inal pain [34-36]; elevated levels of bilirubin and alkaline
phosphatase; and altered levels of thyroid hormones [37].
Severe acute and chronic symptoms include pulmonary
edema and lesions [36,38] and garlic breath and diarrhea
[34,35]. Chronic exposure to high Se doses can lead to
longer prothrombin time (a marker of hepatic injury); alo-
pecia or dry hair and nails; and convulsions, paralysis and
hemiplegia [39-41]. Possible treatments for patients with a
diagnosis of acute Se poisoning are gastric wash and in-
duction of vomiting by use of emetics [34]. Monitoring is
recommended in mild cases (that is, reactions that do not
interfere with activities of daily living), and Se intake may
be indefinitely or temporarily interrupted until the symp-
toms completely disappear in patients with moderate or
severe adverse reactions.
Main objective
Our hypothesis in the present study is that Se supple-
mentation will act as an immune modulator, reducing
the inflammation and injures in the heart over time. Our
aim is to estimate the effects of Se intake on Chagas
heart disease progression, expressed as the decline in left
ventricular ejection fraction (LVEF) (Figure 1).
Specific objectives
The following are our specific objectives:
Patients with the cardiac form of chronic 
Chagas disease (n = 130) with either left 
ventricle segmental dysfunction or mild or 
moderate global dysfunction. 
Randomization
Placebo for 365 days
N = 65
100µg sodium selenitefor 365 days 
N = 65










54% progression rate 27% progression rate 5 years of 
follow-up
Figure 1 Randomization, hypothesis and primary end point.
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http://www.trialsjournal.com/content/15/1/3881. To compare the trajectories of LVEF in both
intervention groups.
2. To estimate and compare the disease progression
incidence rates in both intervention groups.
3. To compare the LVEF average of both intervention
groups at the end of the follow-up period.
4. To estimate the effect of Se intake on quality of life.
5. To estimate the Se intake safety level.
6. To follow Se serum levels during the period of Se
prescription and possible relation to Se toxicity.
7. To describe nutritional status and Se feeding habits.
Methods/design
Ethical considerations
The trial was approved by the Evandro Chagas National
Institute of Infectious Diseases (INI) Research Ethics
Committee (CEP-INI, CAAE 0043.0.009.000-04) and con-
forms to standards currently applied by the Brazilian
National Committee for Research Ethics (CONEP). An
external data safety monitoring board (DSMB) will
monitor this trial to guarantee the quality of the study.
The trial protocol may be altered, with confirmation
from the DSMB, if interim analyses demonstrate statis-
tically significant differences in the primary end point
between groups. If significant beneficial effects of Se
supplementation are found, Se treatment will be offered
to those patients who were randomized to the placebo
group.
Study design and settings
This is a single-center, double-blind, placebo-controlled,
superiority randomized clinical trial. Individuals followedat INI will be recruited to participate in the study. INI is a
national reference center for treatment and research in
infectious diseases and tropical medicine in Brazil. The
majority of patients with suspected Chagas disease in
Rio de Janeiro State are referred to the INI outpatient
unit, either for diagnostic investigation or for specia-
lized health care. At the end of 2012, about 1,100
patients with Chagas disease were followed in an out-
patient unit at INI. This unit is able to proceed with
more than 100 medical appointments per week for
specialized health care for Chagas disease patients.
The unit staff is made up of infectious disease special-
ists, cardiologists, gastroenterologists, nurses, pharma-
cists and exercise physiologists. Resources such as
echocardiography, tomography, 24-hour Holter ECG
monitoring, digestive endoscopy and cardiac rehabili-
tation are also available. Patients receiving health care
at this unit are mostly migrants from rural areas who
are currently living in the Rio de Janeiro metropolitan
area.
Participants
Patients will be recruited sequentially during their
routine outpatient visits. The eligibility criteria are as
follows:
1. A confirmed Chagas disease serological diagnosis
according to the Brazilian consensus diagnostic
investigation recommendation [2].
2. Segmental mild or moderate global left ventricular
systolic dysfunction.
3. Age between 18 and 65 years.
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5. Evidence of nonchagasic heart disease
6. Depression
7. Dysphagia with evidence of food residues in the
esophagus
8. Dysphagia with weight loss higher than 15% of
usual weight in previous four months
9. Medical prescription of vitamins or supplements
10. Residence close to mineral deposits, metal
industries or places with radioactive exposure
11. Participation as a volunteer in other clinical
investigations with interventions
12. Conditions that may result in low protocol
adherence.
Patients who meet the inclusion criteria will be in-
vited to participate in the study, and a signed written
informed consent will be obtained from those patients
willing to participate. Participants will undergo an ini-
tial interview and baseline blood and urine tests. Initial
interviews and tests will include a questionnaire to col-
lect demographic data, medical history, quality of life
and detailed information for a nutritional profile in-
cluding diet Se intake, clinical and cardiovascular exam-
inations (ECG and echocardiography) and biochemical
and hematological laboratory measurements.
Intervention
Patients will receive either 100-μg sodium selenite cap-
sules or placebo capsules to be taken orally after a meal
once daily for 365 days. The placebo capsules will have
the same color, form and texture as those containing Se.
At each visit, patients in both groups will receive the
number of capsules to be taken until the next scheduled
appointment. If, for any reason, treatment interruption
is necessary, then the treatment time will be extended
until the volunteer takes 365 capsules.
Sodium selenite is not commercialized in isolated
form, but is available in combination with other
vitamins and supplements. Therefore, a partnership
was made with Relthy Technology in Pharmaceutical
Services (Indaiatuba, Brazil). That company will be re-
sponsible for providing the capsules of sodium selenite
and placebo for this investigation.
Outcomes
There are two main outcomes that will be evaluated.
(1) The LVEF will be treated as a continuous measure over
time; therefore, the trajectories of both intervention groupswill be compared. (2) Disease progression as a main out-
come measure will be defined as a 10% decrease in the
LVEF, death attributable to Chagas heart disease or hos-
pital admission due to dysrhythmia, stroke or HF attribut-
able to Chagas heart disease.
Four secondary outcomes will be assessed. (1) Disease
progression as a secondary outcome measure will be de-
fined as new findings attributable to Chagas heart dis-
ease, as compared to the previous tests, based on ECGs
(such as intraventricular and atrioventricular node con-
duction disturbances, electrically inactive areas, T-wave
abnormalities, supraventricular and ventricular arrhyth-
mias, bradyarrhythmias, right bundle branch block and
left anterior hemiblock or other findings attributable to
Chagas disease) or echocardiograms (such as segmental
dyskinesia, hypokinesia or akinesia, ventricular aneu-
rysms, global dysfunction or other findings attributable
to Chagas disease). (2) Quality of life will be measured
with the brief version of the World Health Organization
Quality of Life (WHOQOL-Brief ) instrument [42]. (3)
Reversion rates will be based on comparison of ECG or
echocardiogram alterations from previously observa-
tions. (4) Adverse events will be recorded.
Volunteers will be evaluated for 5 years after baseline.
The outcomes will be blindly assessed every 6 months in
the first year. Echocardiography will be conducted every
year from the second to fifth years of follow-up. ECG,
WHOQOL and other clinical outcomes will be assessed
every 6 months from the first to fifth years of follow-up.
Follow-up visits to check for adverse events are planned
to occur every 3 weeks for the first 2 months, every
2 months for the first year and every 6 months from the
second to fifth years of follow-up.
Echocardiographic imaging will be conducted with
a Vivid 7 ultrasound system (GE Medical Systems,
Milwaukee, WI, USA) equipped with a four-matrix trans-
ducer from 2 to 4 MHz. All examination results will be re-
corded and stored in digital media to allow later analysis
at an EchoPAC PC workstation with software version
108.1.12 (GE Medical Systems). The images will be evalu-
ated with the standard left ventricle windows: long and
short left parasternal axes (basal, middle and apical) and
apical three, four and two chambers. All these images
will be recorded with myocardial movements and ECG
tracing. Cardiac dimensions will be measured according
to the recommendations of the European Society of
Echocardiography [43]. LVEF and systolic and diastolic
LV final volumes will be estimated according to Simp-
son’s rule. Segmental analysis will be conducted with
the standard 17 segments description. ECGs will be re-
corded with the standard 12-lead protocol while the pa-
tient is at rest. Digital images of the test will be stored
in a workstation and printed out on graph paper for
later analysis.
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Brief instrument, which was previously validated in a
Brazilian population [42]. It is a generic instrument
that is easy to understand and apply. It consists of 26
questions in 4 dimensions: physical, psychological, so-
cial relationships and environment.
Sample size
We estimated a minimum sample size of 130 volunteers
(65 in the placebo group and 65 in the Se group). In this
estimate calculation, we considered an α error of 0.05, a
β error of 0.20 and a difference in progression risk of
50%. The calculation assumed a progression rate sce-
nario for cardiopathy based on findings for LVEF decline
in a previous cohort study conducted in Brazil (Virgem
da Lapa, State of Minas Gerais) [44]. See Table 1 for
details.
Randomization
A sequence was computer-generated to randomly al-
locate 130 patients into 2 groups in a 1:1 ratio. This
sequence was generated in blocks of 4, 8 and 12
using the “blockrand” extension of the R Project soft-
ware package. This sequence is available only to a
pharmacist not involved in volunteer recruitment.
This pharmacist decided which group would be the
placebo group and which would be the intervention
group by flipping a coin. Next, opaque boxes will be
filled either with placebo or sodium selenite capsules
and later sealed and numbered to correspond to the
computer-generated sequence. As patients undergo
volunteer recruitment by the medical staff, they will
be assigned a number sequentially corresponding to
a treatment box. Therefore, a strategy of numbered
boxes will be used for sequence concealment.
Blinding
Patients, health-care providers and staff involved in out-
come assessment were blinded to treatment. The blind-
ing was conducted using the same strategy of allocation
concealment by numbered boxes. Therefore, numbers
were assigned to volunteers’ treatments, but only one
pharmacist not involved in these tasks will be aware of
what is in each numbered box.Table 1 Minimum sample size estimationa
Parameters Groups
Placebo (n = 65) Selenium (n = 65)
Progression rate 54% 27%
Confidence level 95% 95%
Proportion 1:1 1:1
aEstimate was calculated with an α error of 0.05, a β error of 0.20 and
progression rates in 5 years.Statistical analysis
The type of analysis of major interest is the intention-to-
treat analysis. At baseline, both intervention groups will
be compared concerning information that might modify
disease prognosis to check if random allocation worked
properly at that time. The main analysis will be longitu-
dinal modeling of LVEF by comparing the two interven-
tion groups. This modeling will be conducted with
marginal models and conditional models. This analytical
strategy will also be used for other continuous outcomes,
such as the WHOQOL-Brief.
For each binary outcome of interest, incidence rates will
be estimated and compared among the different interven-
tion groups, including the adverse events discriminated by
severity and causality. Time-dependent survival models
will be adjusted for the binary outcomes, as progression
may occur more than once for each participant. The sur-
vival modeling extension for multiple events of Prentice,
Williams and Peterson will be adopted [45].
Secondary analysis will be conducted as per protocol
by adjusted regression. This secondary analysis will be
conducted mainly if there is an understanding that ran-
dom allocation did not fulfill its purposes at baseline.
REDCap software [46] will be used for data manage-
ment, and data analysis will be conducted with R Project
software [47].
Interim analyses and stopping rules
Four interim analyses are planned. The first will be con-
ducted when the last volunteer completes 6 months of
follow-up, the second will be conducted when the last vol-
unteer completes 18 months of follow-up, the third will be
conducted when the last volunteer completes 30 months
of follow-up and the last will be conducted when the last
volunteer completes 42 months of follow-up. Every interim
analysis will be submitted for DSMB approval.
Trial interruption for ethical reasons may be recom-
mended by the DSMB and confirmed by the trial coordi-
nators or by the trial coordinators and confirmed by the
DSMB. Trial interruption may be recommended due to ei-
ther positive or negative results exceeding expectations.
The prespecified stopping rule is a marginal 10% difference
in LVEF among groups, a reduction of progression rate in
50% or more participants observed at the main outcome
measurement points, an increase of 10% or more of severe
adverse events in one of the intervention groups or serious
adverse events in at least 5% of the volunteers. All these
estimates should have a significance level of 0.01 or less in
any of the interim analyses.
Discussion
This clinical trial presents a possible new therapy based
on the regulation of inflammation and fibrosis with the
potential of delaying the progression of cardiopathy in
Alvarenga Americano do Brasil et al. Trials 2014, 15:388 Page 6 of 7
http://www.trialsjournal.com/content/15/1/388patients with chronic Chagas heart disease. If the hy-
pothesis is confirmed, it will constitute a new contribu-
tion to the improvement of the health care of the
affected population, with prospective application in all of
Latin America, where the WHO registers the existence
of about 10 million infected people [48], and 30% of
them (3 million to 4 million people) are expected to de-
velop the cardiac form. Supplementation with micronu-
trients is simple and has been widely employed by oral
administration [49]. In many countries, including the
United States and France, Se is considered a supplement
instead of a medicine. According to the Brazilian Agency
of Sanitary Inspection, 100 μg of Se is considered medi-
cinal because it is up to 100% of the recommended 34-
μg daily intake. However, the daily level in our trial is
within the limits considered safe (150 μg maximum; Sec-
retariat of Health Surveillance, Ministry of Health (SVS/
MS) Ordinance 40/1998). The inorganic form of Se
(sodium selenite) was chosen because it has been
shown to prevent Keshan cardiopathy, to reduce
electroechocardiographic alterations in patients nou-
rished by the parenteral route and to reduce reinfarction
and cardiac death due to acute myocardial infarction
[50-52]. Because Chagas heart disease progresses slowly
(1% to 3% per year) [5], this clinical trial will last 5 years.
This duration is short compared to the natural progres-
sion rate of this disease. If Se treatment turns out to be
beneficial in this trial, a new and affordable treatment
strategy for Chagas heart disease will be readily avai-
lable for people with chronic T. cruzi infection all over
the world.
Trial status
Participants are currently being recruited.
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